Application of caffeine-halothance contracture test in the diagnosis of malignant hyperthermia

Acta Academiae Medicinae Sinicae

Volumn 30, Issue 2, 2008, Pages 182-186

  Wang, Ying Lin ^a   Gui, Xiang Yang ^a   Xu, Zhong Huang ^a   Huang, Yu Guang ^a   Luo, Ai Lun ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Caffeine halothane contracture test; Diagnosis; Malignant hyperthermia; Treatment

Indexed keywords

CAFFEINE; CREATINE KINASE; HALOTHANE; ISOFLURANE; MYOGLOBIN; RYANODINE RECEPTOR 1; DIAGNOSTIC AGENT; INHALATION ANESTHETIC AGENT; RYANODINE RECEPTOR;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; CREATINE KINASE BLOOD LEVEL; CRYOTHERAPY; DNA SEQUENCE; EXON; GASTRECTOMY; GENE MUTATION; GENETIC SCREENING; GENOME ANALYSIS; HUMAN; HUMAN TISSUE; INHALATION ANESTHESIA; INTRAVENOUS ANESTHESIA; MALE; MALIGNANT HYPERTHERMIA; PROTEIN BLOOD LEVEL; RECTUS ABDOMINIS MUSCLE; URINALYSIS; BLOOD; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; PATHOPHYSIOLOGY; SKELETAL MUSCLE;

ANESTHETICS, INHALATION; CAFFEINE; CREATINE KINASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HALOTHANE; HUMANS; ISOFLURANE; MALIGNANT HYPERTHERMIA; MUSCLE, SKELETAL; MYOGLOBIN; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL;

EID: 44149121958     PISSN: 1000503X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Abraham RB, Adnet P, Glauber V, et al. Malignant hyperthermia [J]. Postgrad Med J, 1998, 74(867): 11-17.
2. Hopkins PM. Malignant hyperthermia: advances in clinical management and diagnosis [J]. Br J Anaesth, 2000, 85 (1): 118-128.
3. Chinese source.
4. Gunilla I, Eva RT. Comparison between the European and North American protocols for diagnosis of malignant hyperthermia susceptibility in humans [J]. Anesth Analg, 1999, 88(5): 1155-1160.
5. Litman RS, Rosenberg H. Malignant hyperthermia: update on susceptibility testing [J]. JAMA, 2005, 293(23): 2918-2924.
6. Chinese source.
7. Sambuughin N, Muldoon S, Barbara BW. Screening of the entire ryanodine receptor type 1 coding region for sequence variants associated with malignant hyperthermia susceptibility in the North American population [J]. Anaesthesiology, 2005, 102(3): 515-521.
8. Mauritz W, Hackl W, Winkler M. Malignant hyperthermia: state of the art [J]. Acta Anaesthesiol Scand, 1997, 111 (suppl): 310-312.
9. McCarthy EJ. Malignant hyperthermia: pathophysiology, clinical presentation, and treatment [J]. AACN Clin Issues, 2004, 15(2): 231-237.
10. Girard T, Treves S, Voronkov E, et al. Molecular genetic testing for malignant hyperthermia susceptibility [J]. Anesthesiology, 2004, 100(5): 1076-1080.
11. Henny R, Joseph F, Sheila M, et al. Testing for malignant hyperthermia [J]. Anaesthesiology, 2002, 96(1): 232-237.
12. Hopkins PM. Recrudescence of malignant hyperthermia [J]. Anesthesiology, 2007, 106(5): 893-894.